Corrigendum to “Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic properties” [Eur. J. Med. Chem. 289 (2025) 117420]
IF 6
2区 医学
Q1 CHEMISTRY, MEDICINAL
引用次数: 0
“具有增强药代动力学特性的新型btk靶向蛋白水解靶向嵌合体（PROTACs）的设计、合成和生物学评价”的更正[欧洲]。医学化学。289 (2025)117420]
余旭芬：写作-原稿、监督、调查、构思。谢琼：监督，概念化。王永辉：监督，概念化。曹涛：调查。向建品：调查。苏华华：调查。Jin Wang：调查。田新建：调查。刘静：调查。荷传作者声明，他们没有已知的可能影响本文所报道工作的竞争性经济利益或个人关系。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍：
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
